Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) was down 3.4% on Tuesday . The company traded as low as $10.10 and last traded at $10.30. Approximately 119,155 shares changed hands during trading, a decline of 64% from the average daily volume of 333,757 shares. The stock had previously closed at $10.66.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded Upstream Bio from a "sell" rating to a "hold" rating in a report on Friday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $56.50.
Read Our Latest Stock Report on Upstream Bio
Upstream Bio Stock Performance
The firm's 50-day simple moving average is $8.60 and its 200-day simple moving average is $11.39.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. As a group, equities research analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Upstream Bio during the 4th quarter valued at $25,000. US Bancorp DE purchased a new position in Upstream Bio during the 4th quarter valued at about $27,000. Legal & General Group Plc bought a new position in Upstream Bio during the 4th quarter valued at approximately $28,000. New York State Common Retirement Fund purchased a new stake in Upstream Bio in the 1st quarter worth approximately $29,000. Finally, Summit Investment Advisors Inc. bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $30,000.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
